based upon numerous assumptions which Martek cannot control
and involve risks and uncertainties that could cause actual results to
differ. These statements should be understood in light of the risk factors
set forth in the company's filings with the Securities and Exchange
Commission, including, but not limited to, the company's Form 10-K for the
fiscal year ended October 31, 2007 and other filed reports on Form 10-K,
Form 10-K/A, Form 10-Q and Form 8-K.
Contact:
Cassie France-Kelly
Public Relations, Martek
(443) 542-2116
media@martek.com
Kyle Stults
Investor Relations, Martek
(410) 740-0081
investors@martek.com
'/>"/>SOURCE Martek Biosciences Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program2.
Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics3.
Synvista Therapeutics to be Featured on Wallst.net4.
Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting5.
Boydens Summit Practice Featured in the September Issue of New Jersey Business Magazine6.
lifesDHA(TM) Featured in New Ricos(R) Cheese Sauce7.
Halal-Certified Products Introduced Into SAFC Supply Solutions Flavors & Fragrances Food-Grade Line8.
National Public Radio (NPR) Features Broadcast Articles on NanoLogix Hydrogen Bioreactor Operation at Welchs Foods9.
Smithfield Foods, Inc. Statement Regarding Animal Cloning10.
Statement of International Dairy Foods Association President and CEO Connie Tipton11.
Senomyx Announces Conclusion of Discovery and Development Collaboration With Kraft Foods Global, Inc.